Coherus BioSciences (CHRS) News Today $1.07 -0.03 (-2.73%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.10 +0.02 (+2.34%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Coherus BioSciences, Inc. (CHRS): A Bull Case TheoryFebruary 12, 2025 | msn.comCoherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyCoherus BioSciences (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving Average - Should You Sell?January 31, 2025 | marketbeat.comCoherus Biosciences: Promising Phase 2 Data and Strategic Valuation Drive Buy RatingJanuary 24, 2025 | markets.businessinsider.comCoherus BioSciences's SWOT analysis: stock faces headwinds amid oncology pivotJanuary 24, 2025 | msn.comCoherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Coherus BioSciences in a research note on Thursday.January 23, 2025 | marketbeat.comCoherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025January 22, 2025 | finance.yahoo.comCoherus Reports Final Phase 2 Casdozokitug Combination Data In Hepatocellular CarcinomaJanuary 22, 2025 | markets.businessinsider.comCoherus Biosciences presents final Phase 2 clinical casdozokitug dataJanuary 22, 2025 | markets.businessinsider.comCoherus Management to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | finance.yahoo.comCoherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Here's WhyCoherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - What's Next?January 8, 2025 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedCoherus BioSciences (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?December 31, 2024 | marketbeat.comCoherus Biosciences to present final Phase 2 casdozokitug combination dataDecember 18, 2024 | markets.businessinsider.comCoherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025December 18, 2024 | globenewswire.comCoherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing DevelopmentDecember 16, 2024 | seekingalpha.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Sees Large Drop in Short InterestCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 30,720,000 shares, a decline of 7.0% from the November 15th total of 33,040,000 shares. Based on an average daily trading volume, of 5,120,000 shares, the days-to-cover ratio is currently 6.0 days.December 16, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $262,000 Stock Holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS)Jacobs Levy Equity Management Inc. cut its position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 74.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 252,330 shares of the biotechnology compDecember 11, 2024 | marketbeat.comDisciplined Growth Investors Inc. MN Trims Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)Disciplined Growth Investors Inc. MN decreased its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 39.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 766,308 shares of the biotechnology company's stock aftDecember 10, 2024 | marketbeat.comCoherus BioSciences, Inc. Common Stock (CHRS)December 9, 2024 | nasdaq.comRedwood City-based Coherus' stock surges after major drug saleDecember 4, 2024 | bizjournals.comCoherus Biosciences Sells UDENYCA Franchise to IntasDecember 4, 2024 | markets.businessinsider.comCoherus Biosciences agrees to divest UDENYCA franchise for up to $558MDecember 4, 2024 | markets.businessinsider.comRaleigh pharmaceutical company expands portfolio with $558M dealDecember 3, 2024 | bizjournals.comCalifornia-Based Biotech Rallies Strongly Following $558.4M DivestitureDecember 3, 2024 | theglobeandmail.comWhy Is Coherus BioSciences Stock Trading Higher On Tuesday?December 3, 2024 | benzinga.comCoherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas PharmaceuticalsDecember 3, 2024 | marketwatch.comCoherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.December 3, 2024 | finance.yahoo.comCoherus BioSciences to divest UDENYCA franchise for up to $558.4MDecember 3, 2024 | msn.comCoherus Management to Participate in the 2024 Citi Global Healthcare ConferenceNovember 27, 2024 | globenewswire.comCoherus Biosciences (CHRS) Receives a Buy from Truist FinancialNovember 20, 2024 | markets.businessinsider.comCoherus Biosciences (CHRS) Receives a Buy from BarclaysNovember 18, 2024 | markets.businessinsider.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Growth in Short InterestCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 31,510,000 shares, a growth of 5.6% from the October 15th total of 29,850,000 shares. Based on an average daily volume of 2,500,000 shares, the days-to-cover ratio is currently 12.6 days.November 17, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases 720,672 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)Los Angeles Capital Management LLC grew its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 344.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 930,132 shares of the biNovember 16, 2024 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comRobert W. Baird Issues Pessimistic Forecast for Coherus BioSciences (NASDAQ:CHRS) Stock PriceRobert W. Baird decreased their price objective on Coherus BioSciences from $8.00 to $4.00 and set an "outperform" rating for the company in a report on Friday.November 8, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Stock, Option ChainNovember 8, 2024 | benzinga.comCoherus Biosciences: Strong Financial Performance and Strategic Cost Management Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comCoherus stock rallies 19% on Q3 earnings, Udenyca production updateNovember 7, 2024 | seekingalpha.comCoherus BioSciences (NASDAQ:CHRS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Coherus BioSciences in a report on Thursday.November 7, 2024 | marketbeat.comCoherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 7, 2024 | finance.yahoo.comCoherus BioSciences Reports Strong Q3 2024 GrowthNovember 7, 2024 | markets.businessinsider.comCoherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comCoherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.comCoherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of EarningsNovember 5, 2024 | finance.yahoo.comCoherus BioSciences (CHRS) to Release Earnings on WednesdayCoherus BioSciences (NASDAQ:CHRS) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comCoherus to Report Third Quarter 2024 Financial Results on November 6, 2024October 30, 2024 | globenewswire.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three haOctober 28, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by StockNews.comStockNews.com downgraded shares of Coherus BioSciences from a "buy" rating to a "hold" rating in a report on Saturday.October 19, 2024 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Sees Large Increase in Short InterestCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 27,960,000 shares, an increase of 11.4% from the September 15th total of 25,090,000 shares. Based on an average daily trading volume, of 2,150,000 shares, the short-interest ratio is currently 13.0 days.October 17, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Stock, Guidance And ForecastOctober 12, 2024 | benzinga.comCoherus BioSciences (NASDAQ:CHRS) Stock Quotes, Forecast and News SummaryOctober 12, 2024 | benzinga.com Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Media Mentions By Week CHRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRS News Sentiment▼0.000.60▲Average Medical News Sentiment CHRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRS Articles This Week▼02▲CHRS Articles Average Week Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Autolus Therapeutics News Valneva News Xeris Biopharma News Tectonic Therapeutic News MeiraGTx News Mineralys Therapeutics News Entrada Therapeutics News Cartesian Therapeutics News Humacyte News Arcturus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHRS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts